Yousif Capital Management LLC Acquires 1,554 Shares of Insulet Co. (NASDAQ:PODD)

Yousif Capital Management LLC grew its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,652 shares of the medical instruments supplier's stock after buying an additional 1,554 shares during the period. Yousif Capital Management LLC's holdings in Insulet were worth $3,042,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PODD. Blue Trust Inc. raised its stake in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the period. Friedenthal Financial bought a new stake in shares of Insulet during the 4th quarter valued at $57,000. TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares during the period. Finally, Versant Capital Management Inc raised its stake in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after purchasing an additional 157 shares during the period.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Insulet Trading Down 1.7 %

NASDAQ PODD traded down $4.71 on Wednesday, hitting $279.55. The company's stock had a trading volume of 671,196 shares, compared to its average volume of 526,167. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company's 50-day simple moving average is $270.94 and its 200 day simple moving average is $242.89. The firm has a market cap of $19.61 billion, a P/E ratio of 47.87, a PEG ratio of 3.61 and a beta of 1.23.

Wall Street Analyst Weigh In

PODD has been the topic of a number of analyst reports. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research note on Thursday, December 12th. Barclays boosted their price objective on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Morgan Stanley upped their target price on Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Canaccord Genuity Group upped their target price on Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Finally, Sanford C. Bernstein started coverage on Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and a consensus target price of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.